Theodore Pincus to Biological Products
This is a "connection" page, showing publications Theodore Pincus has written about Biological Products.
Connection Strength
1.165
-
Documenting the value of care for rheumatoid arthritis, analogous to hypertension, diabetes, and hyperlipidemia: is control of individual patient self-report measures of global estimate and physical function more valuable than laboratory tests, radiographs, indices, or remission criteria? J Rheumatol. 2013 Sep; 40(9):1469-74.
Score: 0.436
-
Treat-to-target: not as simple as it appears. Clin Exp Rheumatol. 2012 Jul-Aug; 30(4 Suppl 73):S10-20.
Score: 0.411
-
Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist. Clin Exp Rheumatol. 2013 Jul-Aug; 31(4 Suppl 78):S1-3.
Score: 0.110
-
RAPID3, an index of only 3 patient self-report core data set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71(2):117-20.
Score: 0.104
-
Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S9-19.
Score: 0.104